A review of venous thromboembolism in COVID-19: A clinical perspective.
Reads0
Chats0
TLDR
There are numerous studies and guidelines for administration of thromboprophylaxis for Coronavirus disease-19 cases as mentioned in this paper, however, there is no consensus on this issue.Abstract:
Coronavirus disease-19 (COVID-19) started in Wuhan, China in December 2019 and spread to all around the world in a short period of time. Hospitalized patients with COVID-19 mostly could suffer from an abnormal coagulation activation risk with increased venous thrombosis events and a poor clinical course. The reported incidence rates of thrombotic complications in hospitalized COVID-19 patients vary between 2.6 and 85% (both in non-critically ill and critically ill patients). The risk of venous thromboembolism is not known in non-hospitalized patients with COVID-19. There are numerous studies and guidelines for administration of thromboprophylaxis for COVID-19 cases. All hospitalized COVID-19 patients should take pharmacological thromboprophylaxis if there is no contraindication. However, there is no consensus on this issue. In this review, we discussed all these approaches in a critical perspective.read more
Citations
More filters
Journal ArticleDOI
Understanding the Co-Epidemic of Obesity and COVID-19: Current Evidence, Comparison with Previous Epidemics, Mechanisms, and Preventive and Therapeutic Perspectives.
Maria Dalamaga,Gerasimos Socrates Christodoulatos,Irene Karampela,Natalia G. Vallianou,Caroline M. Apovian +4 more
TL;DR: Mechanistic and large epidemiologic studies using big data sources with omics data exploring genetic determinants of risk and disease severity as well as large randomized controlled trials (RCTs) are necessary to shed light on the pathways connecting chronic subclinical inflammation/meta-inflammation with adverse COVID-19 outcomes and establish the ideal preventive and therapeutic approaches for patients with obesity.
Journal ArticleDOI
Risk Management and Treatment of Coagulation Disorders Related to COVID-19 Infection.
Christian Zanza,Fabrizio Racca,Yaroslava Longhitano,Andrea Piccioni,Francesco Franceschi,Marco Artico,Ludovico Abenavoli,Aniello Maiese,Giovanna Passaro,G. Volonnino,Raffaele La Russa +10 more
TL;DR: In this paper, a review of the evaluation and management of coagulation abnormalities in individuals with Coronavirus disease 2019 (COVID-19) is presented, and the risk for venous thromboembolism is markedly increased, especially in patients in the intensive care unit.
Journal ArticleDOI
The Impact of SARS-CoV-2 Infection on Blood Coagulation and Fibrinolytic Pathways: A Review of Prothrombotic Changes Caused by COVID-19.
Mehran Bahraini,Akbar Dorgalaleh +1 more
TL;DR: In this paper, a narrative review describes current knowledge of the pathophysiological mechanisms of COVID-19-associated coagulopathy, with focus on prothrombotic changes in hemostatic mediators, including plasma levels of clotting factors, natural anticoagulants, components of fibrinolytic system, and platelets.
Journal ArticleDOI
Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism
TL;DR: In this paper , the authors highlight the association of dysregulated inflammatory cytokines and growth factors with thrombotic complications and coagulopathy in COVID-19 patients and highlight that platelets play key thromboinflammatory roles linking coagulation to immune mediators in a variety of infections including response to viral infection.
Journal ArticleDOI
Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism.
TL;DR: In this article, the authors highlight the association of dysregulated inflammatory cytokines and growth factors with thrombotic complications and coagulopathy in COVID-19 patients and highlight that platelets play key thromboinflammatory roles linking coagulation to immune mediators in a variety of infections including response to viral infection.
References
More filters
Journal ArticleDOI
Platelets Can Associate with SARS-Cov-2 RNA and Are Hyperactivated in COVID-19.
Younes Zaid,Florian Puhm,Isabelle Allaeys,Abdallah Naya,Mounia Oudghiri,Loubna Khalki,Youness Limami,Nabil Zaid,Khalid Sadki,Rafiqua Ben El Haj,Wissal Mahir,Lamiae Belayachi,Bouchra Belefquih,Amina Benouda,Amine Cheikh,Marc-André Langlois,Yahia Cherrah,Louis Flamand,Fadila Guessous,Eric Boilard +19 more
TL;DR: It is demonstrated that platelets release their alpha- and dense-granule contents in both nonsevere and severe forms of COVID-19, as they release various sets of molecules through the different stages of the disease.
Journal ArticleDOI
The stimulation of thrombosis by hypoxia
TL;DR: The Hif-dependent and HIF-independent signaling pathways that regulate thrombus formation under hypoxic conditions are reviewed and could lead to the development of novel prophylactic therapies for thrombosis.
Journal ArticleDOI
Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands.
Matthijs Oudkerk,Harry R. Büller,Dirkjan Kuijpers,Nick van Es,Sytse F. Oudkerk,Theresa C. McLoud,Diederik Gommers,Jaap van Dissel,Hugo ten Cate,Edwin J R van Beek +9 more
TL;DR: Evidence for thromboembolic disease, potential diagnostic and preventive actions as well as recommendations for patients with COVID-19 infection are summarized.
Journal ArticleDOI
Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?
Marco Cattaneo,Elena Bertinato,Simone Birocchi,Carolina Brizio,Daniele Malavolta,Marco Manzoni,Gesualdo Muscarella,Michela Orlandi +7 more
TL;DR: Treatment by low, prophylactic doses of low molecular weight heparin (LMWH) is recommended for acutely ill medical patients at heightened risk for venous thromboembolism, a term that combines deep vein thrombosis (DVT) and its more severe complication, pulmonary embolism.
Journal ArticleDOI
COVID-19 Complicated by Acute Pulmonary Embolism
TL;DR: Two cases from Wuhan, China, presenting with fever, cough, and dyspnea secondary to COVID-19 (formerly known as 2019 novel coronavirus [2019-nCoV]) pneumonia, confirmed with real-time fluorescence polymerase chain reaction test and presenting with typical findings at CT are reported.